Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Acceptance and Commitment Therapy (ACT) Versus Cognitive Behavioural Therapy (CBT) for Fear of Cancer Recurrence (FCR) in Cancer Survivors and Their Spouses (CARE-Pilot)

5 de agosto de 2026 atualizado por: PD Dr. Christina Sauer, University Center of Tumor Diseases, Frankfurt University Hospital

Coping With Fear of Cancer Recurrence (CARE-pilot): Acceptance and Commitment Therapy (ACT) Versus Cognitive Behavioural Therapy (CBT) for Fear of Cancer Recurrence (FCR) in Cancer Survivors and Their Spouses: a 2-arm Randomized Controlled Feasibility Trial

Fear of cancer recurrence (FCR) is one of the most significant psychological burdens faced by cancer survivors. FCR describes the fear, worry, or concern relating to the possibility that cancer will come back or progress, and is associated with reduced quality of life as well as other psychological symptoms. Approximately 60% of cancer survivors suffer from FCR, 20% of whom suffer from severe FCR. Relatives are also burdened by FCR, which in turn negatively affects the dyadic relationship as well as the survivors' quality of life. However, to date, there is a lack of evidence-based psycho-oncological couple interventions that focus on patients'/survivors' and spouses' FCR. Meta-analyses indicate the efficacy of mindfulness- and acceptance-based approaches such as acceptance and commitment therapy (ACT) for reducing FCR. In contrast to traditional Cognitive Behavioral Therapy (CBT) approaches, which, for instance, aim to change thoughts and feelings by cognitive restructuring, ACT aims to increase psychological flexibility and promotes a more detached, acceptance-based attitude toward thoughts and feelings, as well as a value-based life orientation. However, the empirical evidence for ACT in relation to FCR still needs to be investigated more thoroughly.

This study, coping with fear of cancer recurrence (CARE-pilot), addresses these research gaps and aims to test the feasibility and preliminary efficacy of a manualized ACT couple intervention for outpatient cancer survivors (defined as cancer patients who completed primary treatment and were diagnosed < 5 years ago) and their spouses. Sixty-four couples in which either survivor, spouse or both have elevated FCR will be randomized to either the ACT couple intervention (IG) or the traditional CBT couple intervention (active control group, CG). The IG and CG interventions consist of six psychotherapy sessions (four couple sessions and two individual sessions), the content of which is intensified in online modules between sessions (blended care). The primary endpoint of the feasibility study is the retention rate and achievement of recruitment targets. Using standardized measurements, changes in FCR, quality of life (primary endpoint of preliminary efficacy), and other psychosocial variables will be assessed at post-intervention and 3 months after the end of the intervention.

The feasibility study represents the first step in evaluating the feasibility and the practicality of the couple interventions. The CARE-Pilot study aims to evaluate the feasibility and preliminary efficacy of an ACT-based couple intervention in reducing FCR, compared to a CBT-based couple intervention, in couples navigating cancer survivorship.

Visão geral do estudo

Descrição detalhada

Introduction: Fear of cancer recurrence (FCR) is one of the most significant psychological burdens faced by cancer survivors and their romantic partners. However, to date, there is a lack of evidence-based psycho-oncological couple interventions that focus on patients'/survivors' and spouses' FCR. Therefore, this multicenter feasibility trial aims to test the feasibility and preliminary efficacy of a manualized ACT couple intervention for outpatient cancer survivors and their spouses compared with a CBT couple intervention.

Methods and analysis: This is a prospective, multicenter, randomized, controlled pilot trial comparing an ACT couple intervention with a CBT couple intervention. The sample will consist out of adult cancer survivors with a confirmed ICD-10 diagnosis of any cancer site after completed primary oncological treatment and their intimate partners. Time since diagnosis of survivors is <5 years. Survivors and/or their partner will suffer from elevated FCR. The investigators aim to include n = 64 dyads within two German comprehensive cancer centers.

ACT and CBT couple intervention will be delivered by clinical psychologists face-to-face or per video sessions, consisting of six sessions (four couple sessions, two individual sessions). For both trial conditions, online content (e.g. exercises or readings) will be available to deepen session content.

Primary outcomes will be feasibility parameters (retention and recruiting rate) and preliminary efficacy (FCR of survivors and partners). Secondary outcomes will be further feasibility variables (satisfaction with the intervention, treatment fidelity) as well as psychological parameters (e.g. QoL, psychological burden), and dyadic and somatic parameters (e.g. dyadic coping, symptom interference). Explorative outcomes are ACT-based (e.g. psychological flexibility, acceptance, value-based living). The feasibility study represents the first step in evaluating the feasibility and the practicality of the couple interventions in preparation of a full power multicenter RCT. Due to its dyadic approach, our ACT couple intervention has the potential to expand the range of psychological treatment options with ecological valid treatment for reducing FCR.

Tipo de estudo

Intervencional

Inscrição (Estimado)

128

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

Patients

  • cancer survivors (male/female/diverse) with any cancer entity
  • after completed primary treatment (not including endocrine treatment, which can be ongoing)
  • < five years after primary diagnosis
  • FCR (FoP-Q-SF total score ≥ 34) or spouses' FCR (FoP-Q-SF/P total score ≥ 34)
  • living in a partnership or marriage (homo- or heterosexual, divers)

Spouses

  • male/female/diverse spouse of a cancer survivor
  • FCR (FoP-Q-SF/P total score ≥ 34) or patients' FCR (FoP-Q-SF total score ≥ 34)

Patients and spouses:

  • age ≥18 years
  • fluency in the German language
  • able to participate in the 6-week intervention (one session per week)
  • written informed consent

Exclusion Criteria:

Patients:

- metastatic disease

Patients and spouses:

  • both patient and spouse show low FCR (FoP-Q-SF total score < 34 or FoP-Q-SF/P total score < 34)
  • individuals who previously (last 2 years) participated in an ACT-, CBT-, or mindfulness-based psychosocial intervention (psycho-oncological or psychotherapeutic interventions)
  • severe psychiatric disorders and suicidality

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: ACT-couple intervention for FCR
ACT couple intervention for FCR, including 4 couple sessions and 2 single sessions for patients and spouses + access to a digital intervention
The ACT couples intervention comprises six sessions, consisting of four couples' sessions and two individual sessions for cancer survivors and their partners. The first and last sessions are held face-to-face and last 90 minutes. For the other sessions, couples can choose between face-to-face sessions or video-based sessions via a video conferencing tool. These sessions last 60 minutes. All ACT flexibility skills are covered. In addition, couples are given access to an online platform (CoupleACT). Through this platform, participants receive ACT-specific audio files, homework assignments and written material to help them consolidate the content covered in the sessions.
Comparador Ativo: CBT-couple intervention for FCR
CBT couple intervention for FCR, including four couple sessions and two single sessions for patients and spouses + access to a digital intervention
CBT: six sessions, comprising four couples' sessions and two individual sessions for cancer survivors and their partners. The first and last sessions are held face-to-face and last 90 minutes. For the other sessions, couples can choose between face-to-face sessions or video-based sessions via a video conferencing tool. These sessions last 60 minutes. The CBT couples intervention is based on an evaluated group therapy manual (Waadt et al., 2011). It has been adapted for the couples' context and includes, amongst other things, behavioural analysis (SORK), psychoeducation, exposure, cognitive restructuring and mindfulness training. In addition, couples are given access to an online platform (CoupleCare). Through this platform, participants receive CBT-specific audio files, homework assignments and written material to reinforce the content covered in the

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Fear of Progression Questionnaire (FoP-Q-SF) and partner version (FoP-Q-SF/P)
Prazo: From screening to three months follow up

We will assess FCR with the 12-item short form of the Fear of Progression Questionnaire (FoP-Q-SF), which is highly reliable and valid to assess FCR (68, 69). Also a validated partner version exists (FoP-Q-SF/P) which shows high reliability. (Primary outcome for preliminary efficacy).

Response scale: 1-5, min. 12, max. 60. Higher scores = worse outcome (higher fear of progression); score ≥ 34 = clincial cut-off.

From screening to three months follow up
feasibility outcomes: retention and recruiting rate
Prazo: screening to up to seven weeks (post-intervention)
screening to up to seven weeks (post-intervention)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Short-Form Health Survey (SF-12), Physical (PCS) and Mental (MCS) Component
Prazo: baseline to three-months follow-up
Health-related quality of life (HRQoL), 12 items; norm-based 0-100 scoring Min. = 0, max = 100. Higher scores = better outcome (better health-related quality of life)
baseline to three-months follow-up
Personal Health Questionnaire, depression module (PHQ-9)
Prazo: baseline to three-months follow-up
Assessment of depressive symptoms with 9 items, 4-point Likert scale (0-3), Min = 0; max = 27; higher scores = worse outcome (higher depression severity)
baseline to three-months follow-up
Generalized Anxiety Disorder scale (GAD-7)
Prazo: baseline to three-months follow-up
Assessment of anxiety symptoms with 7 items; 4-point Likert scale (0-3). Min = 0; max = 21. Higher scores = worse outcome (higher anxiety severity)
baseline to three-months follow-up
National Comprehensive Cancer Network (NCCN) Distress Thermometer
Prazo: baseline to three-months follow-up
Assessment of distress with a single item, visual analogue scale (0-10). Min = 0; max = 10. Higher scores = worse outcome (higher distress).
baseline to three-months follow-up
Comprehensive Assessment of Acceptance and Commitment Therapy Processes (CompACT)
Prazo: baseline to three-months follow-up
Assessment of psychological flexibility with 8 items, 7-point Likert scale (0-6). Min = 0; max = 48. Higher scores = better outcome (higher psychological flexibility)
baseline to three-months follow-up

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Cognitive Fusion Questionnaire (CFQ)
Prazo: baseline to three-months follow-up
Assessment of Cognitive fusion with 7 items, 7-point Likert scale (1-7). Min. = 7, max = 49. Higher scores = worse outcome (higher cognitive fusion)
baseline to three-months follow-up
German version of the Peace, acceptance and equanimity in cancer experience (PEACE)
Prazo: baseline to three-months follow-up

Assessment of two subscales:

  1. acceptance of illness with 5 items, 4-point Likert (1-4), min = 5; max = 20. Higher scores = better outcome (higher peaceful acceptance)
  2. Struggle with Illness with 7 items, 4-point Likert (1-4), min = 7; max = 28. Higher scores = worse outcome (higher struggle with illness)
baseline to three-months follow-up
Valuing Questionnaire
Prazo: baseline to three-months follow-up

Assessment of valued living with two subscales:

  1. Values-consistent living (progress) with 5 items, 7-point Likert scale (0-6), min. = 0, max. = 30. Higher scores = better outcome (higher enactment of values)
  2. Values-inconsistent living (obstruction) with 5 items, 7-point Likert scale (0-6) min.= 0, max = 30. Higher scores = worse outcome (higher interference with valued living)
baseline to three-months follow-up
Dyadic Coping Inventory (DCI)
Prazo: baseline to three-months follow-up
Dyadic coping with 35 items (of 37), 5-point Likert scale (1-5). Min. = 35; max. = 175. Higher scores = better outcome (better dyadic coping)
baseline to three-months follow-up
German version of the M.D. Anderson Symptom Inventory (MDASI-G)
Prazo: baseline to three-months follow-up

Assessment of two subscales:

  1. Symptom severity with 13 items, 0-10. Min. = 0, max. = 130. Higher scores = worse outcome (more severe symptoms)
  2. Symptom interference with daily life with 6 items, 0-10, min.= 0, max. = 60. Higher scores = worse outcome (higher interference)
baseline to three-months follow-up
Brief Fatigue Inventory (BFI)
Prazo: Baseline to three-months follow-up
Assessment of fatigue with 9 items (0-10), Min. = 0, max = 90. Higher scores = higher fatigue
Baseline to three-months follow-up

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Christina Sauer, PD Dr., Frankfurt University Hospital
  • Investigador principal: Gregor Weissflog, Dr., Leipzig University Hospital

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de agosto de 2026

Conclusão Primária (Estimado)

1 de novembro de 2028

Conclusão do estudo (Estimado)

1 de julho de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

23 de julho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

5 de agosto de 2026

Primeira postagem (Real)

6 de agosto de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

6 de agosto de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

5 de agosto de 2026

Última verificação

1 de agosto de 2026

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • 569352800
  • 2025-2311-prospective study (Outro identificador: ethics committee approval number)

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever